Anesiva

About:

Anesiva, Inc., a biopharmaceutical company, engages in the development and commercialization of novel therapeutic treatments for pain

Website: http://anesiva.com

Top Investors: Temasek Holdings, Sofinnova Investments, Alta Partners, InterWest Partners, JPMorgan Partners

Description:

Anesiva, Inc., a biopharmaceutical company, engages in the development and commercialization of novel therapeutic treatments for pain management worldwide. Its lead product candidate includes Adlea, which completed multiple Phase II and Phase III trials for post-surgical, musculoskeletal, and neuropathic pain. The company was formerly known as AlgoRx Pharmaceuticals, Inc., it changed its name to Anesiva, Inc. in 2006. Anesiva, Inc. was founded in 1999 and is headquartered in South San Francisco, California. On January 15, 2010, Anesiva, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the Northern District of California. On June 10, 2014 filed for Chapter 7 bankruptcy.